| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/25/2000 | US6054312 Receptor-mediated gene delivery using bacteriophage vectors |
| 04/25/2000 | US6054297 Preparing humanized immunoglobulin from complimentarity and human framework region; obtaining human and mammalian variable domain sequences, detecting, replacing, and adjusting sequences, detect binding, prepare immunoglobulin |
| 04/25/2000 | US6054292 T-cell receptor protein |
| 04/25/2000 | US6054273 Inhibitors of alternative alleles of genes as a basis for cancer therapeutic agents |
| 04/25/2000 | US6054130 Non-splicing variants of gp350/220 |
| 04/25/2000 | US6054115 Purifying by exposing a mixture of uncoordinated hydroxyalkyl phosphine groups and coordinated hydroxyalkyl phosphine groups to an amine to separate the unbound coordinated groups from the bound uncoordinated groups |
| 04/23/2000 | CA2287562A1 Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
| 04/20/2000 | WO2000022151A1 Parvovirus vectors and their use |
| 04/20/2000 | WO2000022143A2 Protein kinase homologs |
| 04/20/2000 | WO2000022142A2 Cell signaling polypeptides and nucleic acids |
| 04/20/2000 | WO2000022137A2 Selectively replicating viral vectors |
| 04/20/2000 | WO2000022136A2 Recombinant e1a deleted adenoviral vectors |
| 04/20/2000 | WO2000022124A2 Methods and compositions to induce antitumor response |
| 04/20/2000 | WO2000022120A1 (mbp1) polypeptides capable of interacting with oncogenic mutants of the p53 protein |
| 04/20/2000 | WO2000022117A1 Tumor protein |
| 04/20/2000 | WO2000022113A1 ENZYMATIC SYNTHESIS OF ssDNA |
| 04/20/2000 | WO2000021996A2 Methods and compositions for inhibiting neoplastic cell growth |
| 04/20/2000 | WO2000021986A2 Matrix-remodeling genes |
| 04/20/2000 | WO2000021979A2 Cyclic tetrapeptide and their use as histone deacetylase inhibitor |
| 04/20/2000 | WO2000021977A1 Pregnane glucuronides |
| 04/20/2000 | WO2000021965A1 Substituted perhalogenated phthalocyanines |
| 04/20/2000 | WO2000021964A1 Imidazo-benzazepines having cardiovascular, antitumor, antiinfective and anfiinflammatory activity |
| 04/20/2000 | WO2000021961A1 Imidazo-isoquinoline compounds, their compositions and uses |
| 04/20/2000 | WO2000021959A1 4,5-dihydro-isoxazole derivatives and their pharmaceutical use |
| 04/20/2000 | WO2000021956A1 New crystalline modification of 5-fluoro-1-(tetrahydro-2-furyl)-uracyl, and complex compounds based on this modification and having an antitumoral activity |
| 04/20/2000 | WO2000021955A1 Quinazoline derivatives |
| 04/20/2000 | WO2000021927A2 Pyrrole-2,5-diones as gsk-3 inhibitors |
| 04/20/2000 | WO2000021926A2 6-SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS |
| 04/20/2000 | WO2000021573A1 Site-specific labeling of disulfide-containing targeting vectors |
| 04/20/2000 | WO2000021572A2 Hydrogels and water soluble polymeric carriers for drug delivery |
| 04/20/2000 | WO2000021571A1 Ion exchange tumor targeting (iett) |
| 04/20/2000 | WO2000021567A1 Ionic molecular conjugates of n-acylated derivatives of poly(2-amino-2-deoxy-d-glucose) and polypeptides |
| 04/20/2000 | WO2000021560A1 Flt4 (VEGFR-3) AS A TARGET FOR TUMOR IMAGING AND ANTI-TUMOR THERAPY |
| 04/20/2000 | WO2000021551A1 Isolated peptides which bind to hla-b35 molecules |
| 04/20/2000 | WO2000021542A1 Methods for stimulating bone formation |
| 04/20/2000 | WO2000021537A1 Novel indenoisoquinolines as antineoplastic agents |
| 04/20/2000 | WO2000021532A1 Methods for inhibiting bone resorption |
| 04/20/2000 | WO2000021527A2 Oxaliplatinum preparation packaging |
| 04/20/2000 | WO2000021523A1 Methods for regulating bone formation |
| 04/20/2000 | WO2000021521A2 Sertraline oral concentrate |
| 04/20/2000 | WO2000021509A2 Methods of treatment |
| 04/20/2000 | WO2000007616A3 Use of novel agents inducing cell death in synergy with interferons |
| 04/20/2000 | WO2000006605A9 Heterominibodies |
| 04/20/2000 | WO2000005245A3 Inhibitors of urokinase and blood vessel formation |
| 04/20/2000 | WO2000004918A3 Agents for the immunotherapy of tumoral diseases |
| 04/20/2000 | WO2000004866A3 Preparation of thioarabinofuranosyl compounds and use thereof |
| 04/20/2000 | WO2000004052A3 Soluble derivatives of anti-angiogenic peptides |
| 04/20/2000 | WO2000004023A9 Anhydride modified cantharidin analogues useful in the treatment of cancer |
| 04/20/2000 | WO2000003737A3 Water-soluble drugs and methods for their production |
| 04/20/2000 | WO2000001713A9 Diacylglycerol acyl transferase proteins |
| 04/20/2000 | WO1999066917A3 Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid |
| 04/20/2000 | WO1999066037A3 Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
| 04/20/2000 | WO1999064461A3 Monoclonal antibodies, cross-reactive antibodies and method for producing the same |
| 04/20/2000 | WO1999061469A3 Prostate growth-associated membrane proteins |
| 04/20/2000 | WO1999054463A3 Human k+ ion channel and therapeutic applications thereof |
| 04/20/2000 | WO1999048868A9 Heterocyclic classes of compounds for the modulating tyrosine protein kinase |
| 04/20/2000 | DE19847823A1 New 3-(Hetero)aryl-5-aminosulfonyl-1,2,4-thiadiazole derivatives useful as inhibitors of IL-1beta production in treatment of e.g. leukemia, septic shock, hepatitis, AIDS and diseases of locomotor system |
| 04/20/2000 | DE19847107A1 Use of pertussis toxin to prepare a pharmaceutical composition for treating tumors, especially carcinomas or sarcomas |
| 04/20/2000 | DE19845372A1 Verwendung von Katecholderivaten als Proteinaseninhibitoren Using catechol as proteinase inhibitors |
| 04/20/2000 | CA2450824A1 Methods and compositions for inhibiting neoplastic cell growth |
| 04/20/2000 | CA2347653A1 Novel cell signaling polypeptides and nucleic acids |
| 04/20/2000 | CA2347121A1 (mbp1) polypeptides capable of interacting with oncogenic mutants of the p53 protein |
| 04/20/2000 | CA2346943A1 Cyclic tetrapeptide compound and use thereof |
| 04/20/2000 | CA2346775A1 Protein kinase homologs |
| 04/20/2000 | CA2346693A1 Pregnane glucuronides |
| 04/20/2000 | CA2346542A1 Imidazo-benzazepines having cardiovascular, antitumor, antiinfective and antiinflammatory activity |
| 04/20/2000 | CA2346414A1 Imidazo-isoquinoline compounds, their compositions and uses |
| 04/20/2000 | CA2346329A1 Hydrogels and water soluble polymeric carriers for drug delivery |
| 04/20/2000 | CA2346155A1 Enzymatic synthesis of ssdna |
| 04/20/2000 | CA2346066A1 Ionic molecular conjugates of n-acylated derivatives of poly(2-amino-2-deoxy-d-glucose) and polypeptides |
| 04/20/2000 | CA2346038A1 Methods for inhibiting bone resorption |
| 04/20/2000 | CA2346036A1 Methods for regulating bone formation |
| 04/20/2000 | CA2346031A1 Methods for stimulating bone formation |
| 04/20/2000 | CA2345900A1 Selectively replicating viral vectors |
| 04/20/2000 | CA2345211A1 Recombinant e1a deleted adenoviral vectors |
| 04/20/2000 | CA2344465A1 Methods and compositions for inhibiting neoplastic cell growth |
| 04/20/2000 | CA2326675A1 Isolated peptides which bind to hla-b35 molecules |
| 04/20/2000 | CA2314004A1 Matrix-remodeling genes |
| 04/19/2000 | EP0994111A1 Tetrahydrofuran derivatives |
| 04/19/2000 | EP0994102A1 Cyclic derivatives with a cycloalkylenic chain, process for their preparation and pharmaceutical compositions containing them |
| 04/19/2000 | EP0993613A2 Method for recognizing and determining gnrh receptors and the use of gnrh agonists and gnrh antagonists and other gnrh receptor ligands for the treatment with gnrh receptors of tumours originating in the brain and/or nervous system and/or meninges and/or of kaposi sarcoma |
| 04/19/2000 | EP0993468A1 Compositions and methods for activating genes of interest |
| 04/19/2000 | EP0993460A1 Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase |
| 04/19/2000 | EP0993459A1 Compounds useful for inhibition of farnesyl protein transferase |
| 04/19/2000 | EP0993454A1 Benzo(5,6)cyclohepta(1,2b)pyridine derivatives useful for inhibition of farnesyl protein transferase |
| 04/19/2000 | EP0993452A1 Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives |
| 04/19/2000 | EP0993449A1 Quinoline derivatives as pde iv and/or tnf inhibitors |
| 04/19/2000 | EP0993439A1 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
| 04/19/2000 | EP0993437A1 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
| 04/19/2000 | EP0993304A1 Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing an antitumor agent and an hydroxamic acid derivative |
| 04/19/2000 | EP0789711B1 Identification of the p21-waf1 -pcna interaction site and therapeutic applications thereof |
| 04/19/2000 | EP0711297B1 Rapamycin derivative with antimicrobial, anticancer and immunomodulation activity |
| 04/19/2000 | EP0668769B1 Synthetic compositions related to oak bark extrakt, and method of using same |
| 04/19/2000 | EP0550561B1 Purification of cytokeratin fragments |
| 04/19/2000 | CN1251133A Bi or multifunctional molecules based on dendroaspin scaffold |
| 04/19/2000 | CN1251097A Phthalazines with angiogenesis inhibiting activity |
| 04/19/2000 | CN1251092A Certain cyclic thio substitued acylaminoacid amide derivatives |
| 04/19/2000 | CN1251045A Gel delivery vehicles for anticellular proliferative agent |
| 04/19/2000 | CN1250777A 5,10-dihydrodi pyridino [2,3-b: 2,3-e] pyrazine and 5,10 dihydrodipyridino [2,3-b:3,2-3] pyrazine compound, and prepn.therefor |
| 04/19/2000 | CN1250776A Heterodicyclic compound derivatives |